Globe Life’s second quarter results were received positively by the market, as management pointed to steady premium growth in both life and health insurance segments alongside improved agent recruitment. Co-CEO Matt Darden highlighted that exclusive agencies grew agent count sequentially by 6%, signaling potential for sustained future sales. In addition, the company benefited from favorable mortality trends, which reduced policy obligations and supported stronger underwriting margins. Management attributed much of the margin improvement to these mortality gains and operational efficiency initiatives, including administrative expense control and enhanced use of technology to boost sales conversion rates.

Is now the time to buy GL? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Globe Life’s Q2 Earnings Call

• Jack Matten (BMO Capital Markets) asked about how higher earnings guidance translates to statutory income and cash flows, especially the timing of Bermuda reinsurance benefits. Co-CEO Svoboda explained favorable mortality flows through to statutory income, but assumption changes mainly impact GAAP results, and Bermuda’s benefits are expected starting in 2027.
• Andrew Kligerman (TD Securities) questioned the lowered life insurance sales guidance despite agent count growth, probing management’s confidence in a sales rebound. Co-CEO Darden said agent growth leads sales but productivity lags as new agents are trained, with improved sales expected later in 2025 and into 2026.
• Jamminder Singh Bhullar (JPMorgan) sought clarity on the sustainability of direct-to-consumer sales improvement and asked whether the channel had stabilized. Darden confirmed that technology-driven process changes had established a foundation for ongoing growth, with both direct and agency channels benefiting from better lead conversion.
• Elyse Greenspan (Wells Fargo) asked about margin trends in the health business and the impact of sector-wide medical cost headlines. Darden and Svoboda emphasized the stability of Globe Life’s supplemental health margins and noted that recent sector headlines were unrelated to their core business.
• Wilma Jackson Burdis (Raymond James) inquired about the potential for M&A given increased capital from buybacks and Bermuda. Darden reiterated that while M&A is considered opportunistically, the current priority remains share repurchases unless a compelling strategic fit emerges.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will focus on (1) the pace of agent count expansion and the corresponding impact on life and health sales growth, (2) the effectiveness of technology investments in driving higher sales conversion and marketing efficiency, and (3) progress toward regulatory approval and initial transactions for the Bermuda reinsurance affiliate. Continued monitoring of mortality and lapse trends will also be essential for assessing underwriting margins.

Globe Life currently trades at $143, up from $125.17 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.